The US Food and Drug Administration issued a final rule for the de novo classification program on 4 October, increasing clarity for manufacturers whose products might reach market through that pathway.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?